Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK.

The Journal of antimicrobial chemotherapy - 1 Dec 2016

El Bouzidi Kate, White Ellen, Mbisa Jean L, Sabin Caroline A, Phillips Andrew N, Mackie Nicola, Pozniak Anton L, Tostevin Anna, Pillay Deenan, Dunn David T

Abstract excerpt

BACKGROUND: Darunavir is considered to have a high genetic barrier to resistance. Most darunavir-associated drug resistance mutations (DRMs) have been identified through correlation of baseline genotype with virological response in clinical trials. However, there is little information on DRMs that are directly selected by darunavir in clinical settings. OBJECTIVES: We examined darunavir DRMs emerging in clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Cohort Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Darunavir

Share to Drug Resistance, Viral

Share to HIV Infections

Share to HIV Protease Inhibitors

Share to United Kingdom

Source

Open in PubMed Open full text

Identifiers

PMID: 27856703
DOI: 10.1093/jac/dkw343
PMCID: PMC5181398

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK.PMID 27856703Read ↗

In Vivo Emergence of a Novel Protease Inhibitor Resistance Signature in HIV-1 Matrix.Semantic proximity Read ↗

HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy.Semantic proximity Read ↗

In Vivo Emergence of a Novel Protease Inhibitor Resistance Signature in HIV-1 MatrixSemantic proximity Read ↗

Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen.Semantic proximity Read ↗

Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir.Semantic proximity Read ↗

HIV-1 resistance rarely observed in patients using darunavir once-daily regimens across clinical studies.Semantic proximity Read ↗

Selection of HIV-1 for resistance to fifth-generation protease inhibitors reveals two independent pathways to high-level resistance.Semantic proximity Read ↗

Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial.Semantic proximity Read ↗

Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data.Semantic proximity Read ↗

Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors.Semantic proximity Read ↗

Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients.Semantic proximity Read ↗

Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.